How Integrating Genomic and Clinical Data Transforms Clinical Trial Feasibility

Key takeaways: 

• Precision trials demand precision feasibility, but most feasibility assessments are still built on clinical data alone, leaving the biological criteria that define modern eligibility invisible until it’s too late. 

• Genomic stratification transforms trial outcomes. A drug once considered a failure at 10% response rate achieved 60–75% success when administered only to patients whose genomic makeup included a specific EGFR mutation. 

• Drugs with genomic support are 2.6 to 5 times more likely to succeed in clinical trials, making the ability to combine molecular insight with real-world clinical data one of the highest-leverage investments in drug development today. 

 

If you’re heading to SCOPE Europe in Barcelona this October, you already know the pressure. Eligibility criteria are more specific than ever. Enrollment timelines are tighter. And the gap between the patient population you modeled during feasibility and the one you actually find at sites keeps creating expensive surprises. The problem isn’t that your teams aren’t rigorous. The problem is that the tools most organizations still use for feasibility were built for a different era of research.  

 

The era of the blockbuster drug and one-size-fits-all medicine is ending. What’s replacing it demands a fundamentally different approach to finding the right patients before a trial begins. 

 

Traditional feasibility rested on straightforward questions:  

• How many patients have this disease?  

• Where are they located? 

• What treatments have they received?  

 

Those questions were sufficient when therapies were designed for large, relatively homogeneous patient populations and eligibility criteria were defined by observable clinical characteristics. That model no longer reflects the reality of modern research. 

Today’s trials are increasingly defined by far more specific criteria. Researchers are not simply looking for patients with a given diagnosis, but for those with particular mutations, biomarker profiles, or molecular subtypes, alongside defined clinical characteristics and longitudinal outcomes. Eligibility criteria have become more precise, and often, more restrictive. 

The consequences of getting this wrong are familiar to anyone in clinical operations: overestimating eligible populations, struggling to enroll, and making protocol adjustments mid-study, all of which trace back to how cohorts were defined at the outset. Feasibility assessments built on clinical data alone can’t see the biological layer that increasingly determines who qualifies. 

 

What the Gefitinib Story Teaches Us 

The case of Gefitinib makes this concrete. When the drug was first introduced, it was administered broadly to patients with non-small cell lung cancer and appeared to have limited effectiveness. The response rate across that broad population was around 10%, enough for the drug to be considered a failure. 

But researchers later discovered that patients who did respond shared a specific genetic mutation. By identifying that biomarker and targeting the therapy only to patients whose genomic makeup included the EGFR mutation, response rates improved dramatically, jumping to 60–75%. 

 

The key lesson: Gefitinib wasn’t actually a failed drug; it was being tested in the wrong patient population. It was a therapy that required a biomarker to identify who would benefit, marking an early example of how precision medicine could resurrect what appeared to be a clinical failure. 

 

The Data That Explain Why Are Already There, Just Not Connected  

Molecular changes precede physical symptoms by years. Genomic data are already showing real promise in detection, prevention, and treatment across therapeutic areas. The biological drivers of disease, the molecular differences between patients, and the underlying factors that shape treatment response are increasingly understood and increasingly available in genomic datasets that healthcare organizations and research institutions have been building for years. 

Biological and clinical data have developed along parallel paths, owned by different teams, managed in different systems, and stitched together manually when combined at all. To answer a single scientific question, researchers today still need to examine genetic mutations in one system, review clinical characteristics in another, and then attempt to connect the two themselves. The friction this introduces is significant and compounds directly into feasibility risk. 

When key biological signals are missing from a feasibility assessment, the patient profile is incomplete. That incompleteness carries real consequences for study design, cohort selection, and ultimately trial outcomes. 

Precision feasibility depends on the ability to combine molecular insight with real-world clinical understanding, to ensure that the populations identified in theory align with the patients that exist in practice. Drugs with genomic support are 2.6 to 5 times more likely to succeed in clinical trials. The organizations that can assess that support accurately before a trial begins are the ones positioned to act on it. 

 

A Different Kind of Feasibility Is Now Possible  

TriNetX, The Global Truth Engine for Better Human Health®, has connected biological understanding and clinical reality into the same analytical environment, so researchers can move seamlessly from mechanism to outcome, and from hypothesis to evidence. Genomic data, electronic health record (EHR) data, and narrative clinical information can be queried together in a single workflow, without researchers having to navigate separate systems or manually integrate the results themselves. 

That means feasibility assessments can reflect both biological and clinical dimensions from the start. The patients identified in theory can be validated against patients who exist, with the molecular and clinical profile the protocol requires, before enrollment begins. 

The questions that define modern research increasingly live at the intersection of biological and clinical data. Feasibility needs to live there too. 

 

Ready to go deeper? 

Download the full eBook — The Genomics Breakthrough: Biological and Clinical Data Together At Last — to explore the complete connected evidence framework and what it makes possible for research organizations across pharma, healthcare, and academia. 

And if you’ll be at SCOPE Europe in Barcelona on October 13–14, the TriNetX team will be on site and would welcome the conversation. Schedule a meeting with us.